(Q36616523)

English

Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study

scientific article published on March 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 August 2017

Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study (English)

1 reference

Europe PubMed Central

15 August 2017

colorectal cancer

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

author name string

E Van Cutsem

1

1 reference

Europe PubMed Central

15 August 2017

L Dirix

2

1 reference

Europe PubMed Central

15 August 2017

J-L Van Laethem

3

1 reference

Europe PubMed Central

15 August 2017

S Van Belle

4

1 reference

Europe PubMed Central

15 August 2017

M Borner

5

1 reference

Europe PubMed Central

15 August 2017

M Gonzalez Baron

6

1 reference

Europe PubMed Central

15 August 2017

A Roth

7

1 reference

Europe PubMed Central

15 August 2017

R Morant

8

1 reference

Europe PubMed Central

15 August 2017

E Joosens

9

1 reference

Europe PubMed Central

15 August 2017

G Gruia

10

1 reference

Europe PubMed Central

15 August 2017

D Sibaud

11

1 reference

Europe PubMed Central

15 August 2017

H Bleiberg

12

1 reference

Europe PubMed Central

15 August 2017

language of work or name

0 references

publication date

1 March 2005

1 reference

Europe PubMed Central

15 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

15 August 2017

92

1 reference

Europe PubMed Central

15 August 2017

6

1 reference

Europe PubMed Central

15 August 2017

1055-1062

1 reference

Europe PubMed Central

15 August 2017

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6602462

0 references

Impact of body-size measures on irinotecan clearance: alternative dosing recommendations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361950

30 September 2017

Optimizing the use of irinotecan in colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361950

30 September 2017

Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361950

30 September 2017

Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361950

30 September 2017

Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361950

30 September 2017

Phase II trial of irinotecan in patients with metastatic colorectal carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361950

30 September 2017

High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361950

30 September 2017

Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361950

30 September 2017

Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361950

30 September 2017

High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361950

20 September 2018

Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361950

20 September 2018

Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361950

20 September 2018

Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361950

20 September 2018

A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/15756271

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/15756271

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase II clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/15756271

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/15756271

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/15756271

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/15756271

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/SJ.BJC.6602462

1 reference

Europe PubMed Central

15 August 2017

1 reference

Europe PubMed Central

15 August 2017

1 reference

Europe PubMed Central

15 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36616523&oldid=1590520333"